Sera Medicines

Sera Medicines operates as a biologics-focused accelerator that advances next-generation protein therapeutics targeting complex diseases. The company incubates programs internally until key value inflection points are reached, then spins out new companies—such as Tenet Medicines and Navigator Medicines—to drive these assets into the clinic. Notable recent results include the launch of Navigator Medicines with a $100M Series A financing for its lead bispecific antibody program targeting autoimmune disease. Sera’s approach enables rapid progression from discovery through clinical development by leveraging deep expertise across biology, chemistry, antibody engineering, manufacturing, and business operations.